

ILCA School of Liver Cancer, 3rd and 4th DECEMBER 2026

8.30-9.00 Welcome – Reception Ceremony

First Day (Thursday 3rd December 2026)

9.00 – 10.15	Session 1: Liver Research in Latin America: is it possible? Chairs: <i>Dr Marcelo Silva (Austral University Hospital, Argentina)– ILCA member</i> <i>Dr Marco Arrese (President of ALEH, Chile)</i>
9.00 – 9:30	Choosing the best design for the appropriate clinical research question. Alejandro Forner (Spain)– ILCA member How to write a good quality paper?
9.30– 10.00	LATAM publishing records: is it possible to publish in high impact factor journals? Marco Arrese (Chile)– ALEH President.
10.00 – 10.15	Questions & Discussion
10.15 – 10.35	Coffe break
10.35 – 11.15	Session 2: Interpreting survival outcomes from HCC clinical trials. Chairs: <i>Arndt Vogel (Canada)– ILCA member</i> <i>Manuel Mendizabal MD (Argentina)</i>
10.20 – 11.00	Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma. Federico Piñero (Argentina)– ILCA member
11:00 – 11:15	Questions & Discussion
11.15 – 13.00	Session 3: Epidemiology & Surveillance of Liver Cancer. Chairs: <i>Dr. Amit Singal (USA)– ILCA member</i> <i>Dr. Margarita Anders (Austral University Hospital, Argentina)– ILCA member</i>
11.15 – 11:35	Changing epidemiology for HCC: actual trends and changing treatment effect. Is this true? Marco Arrese (President of ALEH, Chile)
11.35 – 12:00	Changing modalities for HCC surveillance: how can these be applicated in clinical practice? Amit Singal (USA)– ILCA member

12.00 – 12.25	Is there any changing etiologic factor for cholangiocarcinoma? Jesús Bañales (Spain)
12.25 – 12.55	How and to whom: surveillance for cholangiocarcinoma. Arndt Vogel (Canada) – ILCA member
13.00 – 14.20	Lunch Break
14.20 – 15.40	Session 4: Liver cancer diagnosis. Clinical Case Scenarios. Mutidisciplinary discussion session. Panel of Discussion: <i>Amit Singal (USA) – ILCA member</i> <i>Federico Diaz Telli (Argentina)</i> <i>Alejandro Forner (Spain)– ILCA member</i>
14.20 – 14.45	Case 1: Surveillance vs Screening Failure. Is it a problem of the screening tool or the surveillance policy? Case Presentation: Dr Margarita Anders (Argentina)– ILCA member
14.45 – 15.05	Case 2: Agreement rate of Li-RADS for liver tumors. Li-RADS: is this the solution for the imaging reports? Case Presentation: Federico Piñero (Argentina)– ILCA member
15.05 – 15.25	Case 3: Unspecific liver nodule with conventional contrast agents. Hepatobiliary contrast agent for liver tumors. Is it necessary? Case Presentation: Manuel Mendizabal (Argentina)
15.25 – 15:40	Questions & Discussion
15.40 – 16:00	Coffe-break
16.00 – 17:20	Session 5: The evolving landscape of therapy for liver cancer for early stages. PRO & CONs: Mutidisciplinary discussion session. Panel of Discussion: <i>Martin Fauda (Argentina)</i> <i>Gonzalo Sapisochin (Spain)– ILCA member</i>
16.00 – 16:15	PRO: Immunotherapy and the concept of “treatable tumor regression”: I go for it! Arndt Vogel (Canada)– ILCA member
16.15 – 16:30 for it!	CONs: Immunotherapy and the concept of “treatable tumor regression”: I don’t go Dr Alejandro Forner (Spain)– ILCA member
16.30 – 16:50	Neo/Adjuvant therapies for HCC and cholangiocarcinoma. Dr Leonardo da Fonseca (Brazil)– ILCA member
16.50 – 17:10	Immunotherapy before liver transplantation for cholangio & HCC: an update. Dr Gonzalo Sapisochin (Spain)– ILCA member
17.10 – 17:20	Questions & Discussion

Second Day (Friday 4th December 2026)

9.00 – 10.00	Session 6: Staging for cholangio & HCC Towards new updated versions of clinical staging systems. Chairs: <i>Amit Singal (USA)– ILCA member</i> <i>Manuel Mendizabal (Argentina)</i>
9.00 – 9:20	The BCLC up-date vs other staging systems. <i>Dr Alejandro Forner (Spain)– ILCA member</i>
9.20 – 9.40	Is the TNM the best staging system for cholangiocarcinoma? <i>Dr Jesús Bañales (Spain)– ILCA member</i>
9.40 – 10.00	Questions & Discussion
10.00 – 10.30	Coffe-break
10.30 – 11.30	Session 7: Loco regional therapies for Liver Cancer. Chairs: <i>Dr. Bruno Sangro (Spain) – ILCA member</i> <i>Dr. Federico Piñero (Argentina)– ILCA member</i> Clinical Case Scenarios Discussion Clinical Case 1: Cirrhotic patient with 1 single lesion 8 cm, with vascular invasion. Clinical Case 2: No radiological response after 2 nd TACE: should we keep <i>pushing</i> ? Clinical Case 3: Progression or vascular invasion after TACE: SIRT as salvage therapy? Clinical Case 4: Immunotherapy in combination with TACE or SIRT. Round Table - Mutidisciplinary Panel: <i>A Vogel, A Singal, B Sangro, G Sapisochin, A Forner.</i>
11.30 – 12.45	Session 8: Systemic treatment for advanced liver cancer. Chairs: <i>Dr Leonardo da Fonseca MD, PhD (Sao Paulo University Hospital, Brazil)</i> <i>Dr. Federico Piñero MD, MSc, PhD (Austral University Hospital, Argentina)</i>
10.50 – 11.10	Choosing the best 1st line therapy: Which one and to whom? <i>Dr. Arndt Vogel (Canada)– ILCA member</i>
11.10 – 11.40	Case presentation: management of adverse events. <i>Dr Federico Piñero (Argentina)– ILCA member</i> Round Table Mutidisciplinary Panel: <i>A Vogel, L da Fonseca, B Sangro.– ILCA members</i>
11.40 – 12.00	Update on systemic therapy for biliary cancer. <i>Dr. Jesús Bañales (Spain)</i>
12.00 – 12.20	HCC progression after first or second line: what is next? <i>Dr. Bruno Sangro (Spain)– ILCA member</i>
12.20 – 12.40	Questions & Discussion
12:45 – 13:00	Closing remarks & ceremony. <i>Dr Federico Piñero (Argentina)– ILCA member</i>